Physician profile
Gregory P Stark
NPI 1962500967
$5,766.24
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $703 · 2021: $920 · 2022: $978 · 2023: $1,126 · 2024: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,907.74 | 2019-2024 | Trelegy Ellipta, Nucala |
| Genentech USA, INC. | $554.83 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $534.40 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.58 | 2019-2023 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $263.50 | 2020-2024 | Glassia |
| Mylan Specialty L.P. | $258.99 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $201.97 | 2021-2022 | |
| Electromed, INC. | $167.52 | 2019-2023 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $164.12 | 2019-2024 | Fasenra |
| Grifols USA, LLC | $156.48 | 2022-2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $152.40 | 2019-2023 | |
| Genzyme Corporation | $132.66 | 2019-2024 | |
| United Therapeutics Corporation | $117.88 | 2021-2024 | Tyvaso |
| Pulmonx Corporation | $95.12 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $93.46 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $91.63 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $79.53 | 2021-2024 | Dupixent |
| Philips North America LLC | $66.28 | 2023-2024 | (Ak6) Vest Therapy |
| Axsome Therapeutics, INC. | $63.41 | 2023 | Sunosi |
| Sanofi Pasteur INC. | $62.41 | 2019-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $44.07 | 2024 | Lumryz |
| Medical Graphics Corporation | $34.38 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $33.38 | 2022 | |
| Inspire Medical Systems, INC. | $26.51 | 2023 | Inspire |
| Paratek Pharmaceuticals, INC. | $25.79 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $25.47 | 2024 | |
| Shire North American Group INC | $24.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.